Scarica l'app Stockscreener
2.59
3.72%
-0.10
Dopo l'orario di chiusura:
2.60
0.01
+0.39%
Precedente Chiudi:
$2.69
Aprire:
$2.71
Volume 24 ore:
1.43M
Relative Volume:
0.38
Capitalizzazione di mercato:
$555.97M
Reddito:
$12.87M
Utile/perdita netta:
$-114.34M
Rapporto P/E:
-2.9956
EPS:
-0.8646
Flusso di cassa netto:
$-79.23M
1 W Prestazione:
+0.00%
1M Prestazione:
+9.28%
6M Prestazione:
+70.39%
1 anno Prestazione:
+15.62%
Intervallo 1D:
$2.575
$2.72
Intervallo di 1 settimana:
$2.34
$2.745
Portata 52W:
$1.05
$3.31
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Nome
Taysha Gene Therapies Inc
Settore
Industria
Telefono
(214) 612-0000
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Confronta TSHA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
2.59 | 687.82M | 12.87M | -114.34M | -79.23M | -0.8646 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-11 | Iniziato | BofA Securities | Buy |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-04-09 | Iniziato | Piper Sandler | Overweight |
| 2023-02-01 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-03-09 | Iniziato | Robert W. Baird | Outperform |
| 2022-03-01 | Iniziato | Wells Fargo | Overweight |
| 2022-02-18 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | Guggenheim | Buy |
| 2021-07-16 | Iniziato | Needham | Buy |
| 2021-06-24 | Iniziato | Truist | Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-06-09 | Iniziato | Wedbush | Outperform |
| 2021-06-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Ripresa | Jefferies | Buy |
| 2021-02-24 | Iniziato | William Blair | Outperform |
| 2021-01-05 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-19 | Iniziato | Goldman | Buy |
| 2020-10-19 | Iniziato | Jefferies | Buy |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Can Taysha Gene Therapies Inc. stock recover from recent declineConsistently profitable trades - jammulinksnews.com
What analysts say about Taysha Gene Therapies Inc. stockGame-changing capital returns - Autocar Professional
Rett bet set includes Neurogene, Taysha gene therapies - BioWorld MedTech
What drives Taysha Gene Therapies Inc. stock priceUnrivaled growth potential - Autocar Professional
Taysha Gene Therapies Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - Autocar Professional
Is Taysha Gene Therapies Inc. a good long term investmentHigh-impact investment strategies - jammulinksnews.com
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $8.17 Consensus PT from Analysts - Defense World
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Why Taysha Gene Therapies Inc. stock attracts strong analyst attentionVerified Return Tips - Newser
What makes Taysha Gene Therapies Inc. stock price move sharplyFree Long-Term Wealth Growth Plan - Newser
How Taysha Gene Therapies Inc. stock performs during market volatilityFree Popular Stock Recommendations - Newser
How did TSHA's Q1 2024 EPS surprise impact short-term traders? - AInvest
Taysha Gene Therapies (NASDAQ:TSHA) Coverage Initiated at Bank of America - Defense World
Biotech Bargains: Finding Gold in the Healthcare Sell-Off - AInvest
Taysha Gene's 5.9% Surge: A Deep Dive into the Unexplained Rally - AInvest
BofA Securities initiates coverage on Taysha Gene Therapies stock with Buy rating - Investing.com Canada
BofA Assigns Buy Rating to Taysha Gene Therapies (TSHA) with $8 Target | TSHA Stock News - GuruFocus
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - MSN
Goldman Sachs Group Inc's Strategic Acquisition in Taysha Gene Therapies Inc - GuruFocus
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Li - GuruFocus
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Gene Therapies (TSHA) Gets a Buy from Wells Fargo - The Globe and Mail
Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock - Nasdaq
Taysha Gene Therapies (TSHA) Receives Buy Rating from Needham | - GuruFocus
Taysha Gene Therapies (TSHA) Receives Buy Rating from Needham | TSHA Stock News - GuruFocus
Cantor Fitzgerald Reiterates “Overweight” Rating on Taysha (TSHA) for Positive TSHA-102 Clinical Data - MSN
Rhumbline Advisers Boosts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Jefferies Maintains a Buy on Taysha Gene Therapies (TSHA) With an $8 PT - Yahoo Finance
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) added to S&P Biotechnology Select Industry Index - MarketScreener
Taysha Gene Therapies’ SWOT analysis: promising Rett syndrome therapy boosts stock outlook - Investing.com Australia
Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):